Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Hematology & OncologyOpen Access

Recent advances in universal chimeric antigen receptor T cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

NJNing JiangZYZhaoyi YangHMHuilei Miao

Discussion

Loading...

Member takes

Overview

Review summarizes recent strategies to enhance universal CAR-T effectiveness, addressing immunological challenges in hematologic cancers.

Key Points

  • Universal CAR-T cells have potential as off-the-shelf therapies, reducing complexity in manufacturing.
  • Innovative engineering approaches, including CRISPR/Cas9, help mitigate graft-versus-host disease and enhance efficacy.
  • Clinical trials show promise for hematological cancers, but challenges persist in treating solid tumors.
  • Integrating advanced cellular engineering with clinical strategies is crucial to fully realize UCAR-T's potential.

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/68c243acb210217d647a7e00https://doi.org/10.1186/s13045-025-01737-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy2025
  2. 2Tracing the development of CAR-T cell design: from concept to next-generation platforms.2025
  3. 3Targeting Cancer at its Core: Cellular and Genetic Approaches Via CAR-T Cell Therapy CAR-T Cell Therapy of Cancer2025
  4. 4Genetic Engineering in CAR T Cells for Solid Tumors: Current State, Barriers and Future Developments.2025
  5. 5Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer2025